ANAB · Anaptysbio, Inc · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $232.39M | $234.6M | $91.28M | $17.16M | $10.29M | $63.18M | $75M | $8M | $5M | $10M | $16.68M | $17.57M | |
| $128.78M | $135.97M | $163.84M | $132.28M | $88.8M | $98.5M | $80.03M | $99.34M | $56.2M | $29.44M | $15.42M | $17.3M | |
| $62.81M | $50.74M | $42.39M | $41.95M | $36.64M | $21.49M | $18.85M | $16.09M | $15.53M | $9.34M | $4.29M | $3.59M | |
| $543K | $559K | $606K | $652K | $675K | $619K | $559K | $514K | $315K | $183K | $233K | $274K | |
| $191.59M | $186.71M | $206.23M | $181.57M | $125.44M | $119.99M | $98.88M | $115.43M | $71.72M | $38.78M | $19.71M | $20.89M | |
| $40.8M | $47.9M | -$114.95M | -$164.41M | -$115.15M | -$56.81M | -$23.88M | -$107.43M | -$66.72M | -$28.78M | -$3.03M | -$3.32M | |
| — | 20.42% | -125.93% | -958.27% | -1119.41% | -89.93% | -31.84% | -1342.9% | -1334.44% | -287.81% | -18.13% | -18.91% | |
| $41.34M | $48.46M | -$114.34M | -$163.76M | -$114.48M | -$56.2M | -$23.32M | -$106.92M | -$66.41M | -$28.6M | -$2.79M | -$3.05M | |
| — | — | — | — | — | $0 | $0 | $1.04M | $1.65M | $1.78M | $458K | $460K | |
| — | — | — | — | — | — | — | — | — | $1.62M | $127K | $18K | |
| -$67.43M | -$60.96M | -$30.28M | $788K | -$13.55M | -$982K | $3.95M | $9.94M | $4.87M | -$1.29M | -$1.23M | -$1.94M | |
| -$26.63M | -$13.07M | -$145.23M | -$163.62M | -$128.7M | -$57.8M | -$19.93M | -$97.49M | -$61.85M | -$30.07M | -$4.26M | -$5.27M | |
| $160K | $164K | $3000 | -$4000 | $24K | $0 | $0 | -$152K | -$192K | $0 | $0 | $139K | |
| -$26.79M | -$13.23M | -$145.23M | -$163.62M | -$128.72M | -$57.8M | -$19.93M | -$97.34M | -$61.66M | -$30.07M | -$4.26M | -$5.41M | |
| — | -5.64% | -159.1% | -953.66% | -1251.33% | -91.49% | -26.57% | -1216.7% | -1233.12% | -300.7% | -25.53% | -30.76% | |
| — | — | — | — | — | — | — | -$97.34M | -$61.66M | -$30.07M | -$4.26M | — | |
| -$27.09M | -$13.56M | -$144.13M | -$159.17M | -$133.55M | -$58.21M | -$20.27M | -$96.78M | -$61.45M | -$30.5M | -$4.26M | -$5.41M | |
| USD/shares | -$0.87 | -$0.31 | -$3.41 | -$4.05 | -$3.05 | -$1.41 | -$0.49 | -$2.40 | -$1.67 | -$1.01 | -$1.08 | — |
| USD/shares | -$0.87 | -$0.31 | -$3.41 | -$4.05 | -$3.05 | -$1.41 | -$0.49 | -$2.40 | -$1.67 | -$1.01 | -$1.08 | — |
| shares | — | 43.14M | 42.57M | 40.39M | 42.25M | 41.15M | 40.95M | 40.59M | 37.01M | 29.67M | 3.96M | 3.83M |
| shares | — | 43.14M | 42.57M | 40.39M | 42.25M | 41.15M | 40.95M | 40.59M | 37.01M | 29.67M | 3.96M | 3.83M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: $119.08M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 270 similar-size Biotechnology companies (of 517 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Royalty Management Company | $234,603,000 | $91,280,000 | $17,157,000 | — |
| Biopharma Company | $0 | $0 | $0 | — |
| Research and Development Segment | — | — | — | $10,287,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Royalty Management Company | $226,902,000 | $66,152,000 | -$45,950,000 | — |
| Biopharma Company | -$179,006,000 | -$181,101,000 | -$118,461,000 | — |
| Research and Development Segment | — | — | — | -$115,154,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Royalty Management Company | 96.7% | 72.5% | -267.8% | — |
| Research and Development Segment | — | — | — | -1119.4% |